AstraZeneca announces results from long-term safety trial of naloxegol in patients with opioid-induced constipation
26 February 2013 | By AstraZeneca
AstraZeneca announced high-level results from KODIAC-08...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
26 February 2013 | By AstraZeneca
AstraZeneca announced high-level results from KODIAC-08...
15 January 2013 | By AstraZeneca
AstraZeneca unveiled changes to its executive leadership team...
13 December 2012 | By AstraZeneca
Top-line results of OSKIRA-4...
11 December 2012 | By AstraZeneca
AstraZeneca and Isis Pharmaceuticals, Inc. announced a strategic alliance...
14 November 2012 | By AstraZeneca
The European Commission has approved FORXIGA™ (dapagliflozin) tablets...
13 November 2012 | By AstraZeneca
Court in Germany has found the formulation patent protecting SEROQUEL XR® prolonged-release tablets to be invalid...
12 November 2012 | By AstraZeneca
AstraZeneca announced positive top-line results from two Phase III trials...
31 October 2012 | By AstraZeneca
Funding for 15 research projects...
23 October 2012 | By AstraZeneca
AstraZeneca and Ironwood Pharmaceuticals, Inc. announced an agreement to co-develop and co-commercialise Ironwood’s linaclotide...
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
12 September 2012 | By AstraZeneca
AstraZeneca PLC has conducted a successful global bond market transaction issuing a total of $2 billion of notes...
3 September 2012 | By Pradeep Sharma and Katherine Fenner, Global DMPK, AstraZeneca R&D
Physiologically based pharmacokinetic (PBPK) models describe the different compartments (tissues) in the body linked via arterial and venous blood flow (Figure 1). The volume of each tissue and blood flows are available from literature data1-5 and PBPK models have been developed for many species including rat, mouse, dog, pig and…
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...